抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 3123人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852932, encodeId=8308185293217, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌, objectType=article, longId=723589, objectId=d350e23589a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d350e23589a7, replyNumber=0, likeNumber=0, createdTime=2022-09-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d350e23589a7, moduleTitle=Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d350e23589a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853040, encodeId=618318530408d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAHA：肾素血管紧张素系统抑制剂在COVID-19患者中的应用情况分析, objectType=article, longId=737151, objectId=bddee3715121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bddee3715121, replyNumber=0, likeNumber=108, createdTime=2023-05-19, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bddee3715121, moduleTitle=JAHA：肾素血管紧张素系统抑制剂在COVID-19患者中的应用情况分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bddee3715121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852924, encodeId=d5e31852924b4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ARD：分析TNF抑制剂的脐带血水平以验证EULAR在怀孕期间使用TNF抑制剂的建议, objectType=article, longId=301704, objectId=4116301e0407, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4116301e0407, replyNumber=0, likeNumber=124, createdTime=2023-01-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4116301e0407, moduleTitle=ARD：分析TNF抑制剂的脐带血水平以验证EULAR在怀孕期间使用TNF抑制剂的建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4116301e0407)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852970, encodeId=ee3e18529e0cc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤, objectType=article, longId=727301, objectId=6669e2730156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6669e2730156, replyNumber=0, likeNumber=84, createdTime=2022-09-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6669e2730156, moduleTitle=Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6669e2730156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852919, encodeId=703b18529197d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAAD：免疫检查点抑制剂介导的银屑病治疗, objectType=article, longId=301386, objectId=1dbe30138633, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dbe30138633, replyNumber=0, likeNumber=69, createdTime=2022-08-03, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dbe30138633, moduleTitle=JAAD：免疫检查点抑制剂介导的银屑病治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dbe30138633)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852929, encodeId=a98318529293b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, objectType=article, longId=302280, objectId=14b430228084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b430228084, replyNumber=0, likeNumber=92, createdTime=2022-08-30, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b430228084, moduleTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14b430228084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853036, encodeId=446418530361b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：新型小分子胸苷酸合成酶抑制剂CT900治疗高级别浆液性卵巢癌, objectType=article, longId=736601, objectId=eecbe3660187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eecbe3660187, replyNumber=0, likeNumber=73, createdTime=2022-12-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eecbe3660187, moduleTitle=Clin Cancer Res：新型小分子胸苷酸合成酶抑制剂CT900治疗高级别浆液性卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eecbe3660187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852895, encodeId=f9e7185289527, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎, objectType=article, longId=299190, objectId=b29229919036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29229919036, replyNumber=0, likeNumber=80, createdTime=2022-10-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29229919036, moduleTitle=JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29229919036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852860, encodeId=24c318528603a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, objectType=article, longId=293561, objectId=cf2c293561b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf2c293561b4, replyNumber=0, likeNumber=79, createdTime=2022-06-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf2c293561b4, moduleTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf2c293561b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852841, encodeId=85991852841ec, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, objectType=article, longId=292042, objectId=cf0429204269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0429204269, replyNumber=0, likeNumber=62, createdTime=2022-01-16, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0429204269, moduleTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf0429204269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852884, encodeId=836f18528843e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BJD:儿童暴露于肿瘤坏死因子抑制剂可能引发银屑病, objectType=article, longId=295224, objectId=a95329522413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a95329522413, replyNumber=0, likeNumber=121, createdTime=2022-02-26, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a95329522413, moduleTitle=BJD:儿童暴露于肿瘤坏死因子抑制剂可能引发银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a95329522413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852918, encodeId=9154185291851, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Thorac Oncol：5项RCT研究合并分析表明质子泵抑制剂(PPIs)使用可降低atezolizumab（阿替利珠单抗）治疗的疗效, objectType=article, longId=301398, objectId=90fb30139881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90fb30139881, replyNumber=0, likeNumber=0, createdTime=2022-07-16, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90fb30139881, moduleTitle=J Thorac Oncol：5项RCT研究合并分析表明质子泵抑制剂(PPIs)使用可降低atezolizumab（阿替利珠单抗）治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90fb30139881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852908, encodeId=a7e5185290877, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JEADV：芳香酶抑制剂治疗乳腺癌患者额部纤维性脱发2例, objectType=article, longId=300631, objectId=fd0f30063134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd0f30063134, replyNumber=0, likeNumber=71, createdTime=2022-06-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd0f30063134, moduleTitle=JEADV：芳香酶抑制剂治疗乳腺癌患者额部纤维性脱发2例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd0f30063134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852789, encodeId=df4a1852e8906, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？, objectType=article, longId=219170, objectId=015e2191e0a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=015e2191e0a9, replyNumber=0, likeNumber=65, createdTime=2022-05-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015e2191e0a9, moduleTitle=Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=015e2191e0a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853009, encodeId=1ae31853009a8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=新一代心肌肌球蛋白抑制剂aficamten在中国获得3期临床试验申请批准，用于治疗症状性梗阻性肥厚型心肌病, objectType=article, longId=730815, objectId=f09be30815b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f09be30815b3, replyNumber=0, likeNumber=74, createdTime=2022-12-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f09be30815b3, moduleTitle=新一代心肌肌球蛋白抑制剂aficamten在中国获得3期临床试验申请批准，用于治疗症状性梗阻性肥厚型心肌病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f09be30815b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853017, encodeId=548c185301e33, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=周清教授 | 首个PD-1抑制剂头对头研究结果在2022 ASCO公布，中国创新药物彰显实力, objectType=article, longId=731997, objectId=1efbe3199786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1efbe3199786, replyNumber=0, likeNumber=92, createdTime=2022-08-03, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1efbe3199786, moduleTitle=周清教授 | 首个PD-1抑制剂头对头研究结果在2022 ASCO公布，中国创新药物彰显实力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1efbe3199786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852848, encodeId=735a185284823, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, objectType=article, longId=292494, objectId=9f45292494ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f45292494ff, replyNumber=0, likeNumber=145, createdTime=2021-12-30, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f45292494ff, moduleTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f45292494ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852994, encodeId=fd7618529942b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！ , objectType=article, longId=729095, objectId=d5c5e2909563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5c5e2909563, replyNumber=0, likeNumber=73, createdTime=2022-11-25, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5c5e2909563, moduleTitle=ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5c5e2909563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852838, encodeId=ab3f1852838e2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BJU Int：非肌层浸润性膀胱癌患者在BCG期间是否应停用纤维蛋白凝块抑制剂？, objectType=article, longId=291860, objectId=69f029186024, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69f029186024, replyNumber=0, likeNumber=69, createdTime=2022-07-03, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69f029186024, moduleTitle=BJU Int：非肌层浸润性膀胱癌患者在BCG期间是否应停用纤维蛋白凝块抑制剂？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69f029186024)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853024, encodeId=a8e9185302425, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Rheumatology：血小板抑制剂在系统性硬化相关指端溃疡中的应用，DU-VASC模型推导和验证, objectType=article, longId=734091, objectId=3bede34091e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bede34091e4, replyNumber=0, likeNumber=78, createdTime=2022-08-26, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bede34091e4, moduleTitle=Rheumatology：血小板抑制剂在系统性硬化相关指端溃疡中的应用，DU-VASC模型推导和验证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bede34091e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌

2022-09-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAHA：肾素血管紧张素系统抑制剂在COVID-19患者中的应用情况分析

2023-05-19

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ARD：分析TNF抑制剂的脐带血水平以验证EULAR在怀孕期间使用TNF抑制剂的建议

2023-01-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤

2022-09-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAAD：免疫检查点抑制剂介导的银屑病治疗

2022-08-03

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究

2022-08-30

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：新型小分子胸苷酸合成酶抑制剂CT900治疗高级别浆液性卵巢癌

2022-12-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎

2022-10-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS

2022-06-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始

2022-01-16

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BJD:儿童暴露于肿瘤坏死因子抑制剂可能引发银屑病

2022-02-26

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Thorac Oncol：5项RCT研究合并分析表明质子泵抑制剂(PPIs)使用可降低atezolizumab（阿替利珠单抗）治疗的疗效

2022-07-16

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JEADV：芳香酶抑制剂治疗乳腺癌患者额部纤维性脱发2例

2022-06-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？

2022-05-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

新一代心肌肌球蛋白抑制剂aficamten在中国获得3期临床试验申请批准，用于治疗症状性梗阻性肥厚型心肌病

2022-12-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

周清教授 | 首个PD-1抑制剂头对头研究结果在2022 ASCO公布，中国创新药物彰显实力

2022-08-03

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用

2021-12-30

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！

2022-11-25

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BJU Int：非肌层浸润性膀胱癌患者在BCG期间是否应停用纤维蛋白凝块抑制剂？

2022-07-03

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Rheumatology：血小板抑制剂在系统性硬化相关指端溃疡中的应用，DU-VASC模型推导和验证

2022-08-26

科室
- - 订阅+
  - 更多科室
工具
服务